SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will
GlobeNewswireApr 18 07:00 ET
Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year
Seeking AlphaMar 10 13:08 ET
Correction to SpringWorks Therapeutics Rating on March 6
JP Morgan raised its price target on SpringWorks to $75.00/share from $74.00/share. "SpringWorks Therapeutics Price Target Raised to $74.00/Share From $73.00 by JP Morgan" at 6:49 a.m. ET on March 6 i
Dow JonesMar 8 11:04 ET
SpringWorks Therapeutics Price Target Raised to $74.00/Share From $73.00 by HC Wainwright & Co.
SpringWorks Therapeutics Price Target Raised to $74.00/Share From $73.00 by HC Wainwright & Co.
Dow JonesMar 6 08:37 ET
SpringWorks Therapeutics Is Maintained at Overweight by JP Morgan
SpringWorks Therapeutics Is Maintained at Overweight by JP Morgan
Dow JonesMar 6 06:49 ET
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Springworks Therapeutics (SWTX) and Genmab (GMAB)
TipRanksMar 6 06:40 ET
Express News | JP Morgan Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $74
Moomoo 24/7Mar 6 06:38 ET
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment
SpringWorks Therapeutics (SWTX) said Monday it has begun a rolling submission of a new drug application for mirdametinib, a drug candidate to treat neurofibromatosis type 1, a rare genetic disorder th
MT NewswiresMar 4 11:28 ET
SpringWorks Therapeutics Has Initiated A Rolling Submission Of A New Drug Application To FDA For Mirdametinib In Pediatric And Adult Patients With Neurofibromatosis Type 1-associated Plexiform Neurofibromas; Expected To Complete By Q2 Of 2024
SpringWorks Therapeutics Has Initiated A Rolling Submission Of A New Drug Application To FDA For Mirdametinib In Pediatric And Adult Patients With Neurofibromatosis Type 1-associated Plexiform Neurofi
BenzingaMar 4 06:37 ET
Express News | SpringWorks Therapeutics Announces European Medicines Agency Validation For Marketing Authorization Application Of Nirogacestat For Treatment Of Adults With Desmoid Tumors
Moomoo 24/7Feb 29 09:02 ET
SpringWorks Therapeutics Is Maintained at Overweight by Barclays
SpringWorks Therapeutics Is Maintained at Overweight by Barclays
Dow JonesFeb 29 08:37 ET
Express News | Barclays Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $63
Moomoo 24/7Feb 29 08:26 ET
Analysts' Top Healthcare Picks: Ligand Pharma (LGND), Springworks Therapeutics (SWTX)
TipRanksFeb 29 06:30 ET
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Tarsus Pharmaceuticals (TARS) and Springworks Therapeutics (SWTX)
TipRanksFeb 28 05:50 ET
Springworks Therapeutics: A Buy Rating on Ogsiveo's Success and Promising Pipeline
TipRanksFeb 28 05:50 ET
Express News | SpringWorks Therapeutics Shares Are Trading Higher After the Company Reported Q4 Financial Results
Moomoo 24/7Feb 27 11:48 ET
Springworks Therapeutics: A Strong Buy on Ogsiveo's Market Triumph and Growth Potential
TipRanksFeb 27 10:35 ET
Analysts Offer Insights on Healthcare Companies: Telesis Bio (TBIO) and Springworks Therapeutics (SWTX)
TipRanksFeb 27 10:20 ET
SpringWorks Therapeutics: Q4 Earnings Insights
SpringWorks Therapeutics (NASDAQ:SWTX) reported its Q4 earnings results on Tuesday, February 27, 2024 at 06:30 AM.Here's what investors need to know about the announcement.EarningsSpringWorks Therapeu
BenzingaFeb 27 09:00 ET
SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results
Yahoo FinanceFeb 27 07:12 ET
No Data
No Data